CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 87 enrolled
Drug / intervention
Cohortingother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05270980
NCT05270980N/ACompleted

COVID-19 Serologic Strategies for Skilled Nursing Facilities (CERO)

NYU Langone Health·interventional·Posted Mar 8, 2022·Updated Apr 6, 2023

In Brief

A clinical study evaluating Cohorting for COVID-19. Completed, enrolled 87 participants across 2 sites.

Detailed Summary

The COVID-19 pandemic ravaged United States skilled-nursing facilities (SNFs). Novel strategies that maximize the safety and quality of life for SNF residents with ADRD and staff who care for them are urgently needed. Thus, the study's objectives are: 1. To rapidly plan and pilot test an intervention that leverages COVID-19 antibody and PCR status to pair SNF staff with residents in the safest way possible 2. To reduce reduced COVID-19 incidence rate compared to SNFs not using this novel staff-resident assignment strategy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMar 8, 2022
Enrollment StartAug 11, 2021
Primary CompletionFeb 4, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.3 years ago

Interventions

Cohortingother

The cohorting strategy will result in "pairing" serology-positive staff with serology-negative residents and serology-negative staff and serology-positive residents to the degree that penetration of serologic presumed immunity allows this pairing to be positive. Any resident who refuses serology testing will be treated as if they are serology negative as the safest strategy for risk of unwanted exposure.